Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults

Tim R Cressey; Ram Yogev; Andrew Wiznia; Rohan Hazra; Patrick Jean-Philippe; Bobbie Graham; Amy Gonzalez; Paula Britto; Vincent J Carey; Courtney V Fletcher; Edward P Acosta; IMPAACT P1058A Team

doi:10.1093/jpids/piw017

Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults

J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):294-296. doi: 10.1093/jpids/piw017.

Authors

Affiliations

¹ Program for HIV Prevention and Treatment, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Thailand.
² Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
³ Jacobi Medical Center, Bronx, New York.
⁴ National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development, Maternal and Pediatric Infectious Disease Branch.
⁵ The Henry M. Jackson Foundation-Division of AIDS, a Division of The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Contractor to National Institute of Allergy and Infectious Diseases, NIH, US Department of Health and Human Services, Bethesda, Maryland.
⁶ Frontier Science & Technology, Amherst, New York.
⁷ Harvard School of Public Health, Boston, Massachusetts.
⁸ University of Nebraska Medical Center, Omaha.
⁹ University of Alabama at Birmingham.

Abstract

Data on the combination of darunavir/ritonavir and etravirine both given twice daily in adolescents/young adults are lacking. In this study, we assessed the pharmacokinetics of darunavir/ritonavir 600/100 mg with etravirine 200 mg twice daily in 36 treatment-experienced human immunodeficiency virus-infected adolescents and young adults and found that exposures were comparable to those reported in adults.

Keywords: antiretrovirals; darunavir; etravirine; pediatrics; ritonavir.

Publication types

Clinical Trial
Multicenter Study
Observational Study

MeSH terms

Adolescent
Darunavir / administration & dosage
Darunavir / pharmacokinetics*
Darunavir / therapeutic use
Drug Administration Schedule
Drug Combinations
Female
HIV Infections / drug therapy*
HIV Protease Inhibitors / administration & dosage
HIV Protease Inhibitors / pharmacokinetics*
HIV Protease Inhibitors / therapeutic use
Humans
Male
Nitriles
Pyridazines / administration & dosage
Pyridazines / pharmacokinetics*
Pyridazines / therapeutic use
Pyrimidines
Reverse Transcriptase Inhibitors / administration & dosage
Reverse Transcriptase Inhibitors / pharmacokinetics*
Reverse Transcriptase Inhibitors / therapeutic use
Ritonavir / administration & dosage
Ritonavir / pharmacokinetics*
Ritonavir / therapeutic use
Viral Load / drug effects
Young Adult

Substances

Drug Combinations
HIV Protease Inhibitors
Nitriles
Pyridazines
Pyrimidines
Reverse Transcriptase Inhibitors
etravirine
Ritonavir
Darunavir

Grants and funding

UM1 AI068616/AI/NIAID NIH HHS/United States